Biotech News

Regeneron Announces Investor Conference Presentations

Regeneron Pharmaceuticals (REGN)Regeneron Pharmaceuticals2026-04-20 20:05 ESTConference / presentation

TARRYTOWN, N.Y., April 20, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: • BofA Securities Health Care Conference 2026 at 10:00 a.m. PT ( 1:00 p.m. ET) on Tuesday, May 12, 2026 • Goldman Sachs 47 th Annual Global Healthcare

Open original release

Related news

BMEABiomea Fusion2026-05-05 21:51 EST

Biomea Fusion Announces Poster Presentations of Icovamenib at the American Diabetes Association (ADA) 86th Scientific Sessions

EXELExelixis2026-05-27 20:05 EST

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in June

RVMDRevolution Medicines2026-05-21 20:05 EST

Revolution Medicines to Host Investor Conference Call on Positive RASolute 302 Results Following 2026 ASCO Presentation

EXELExelixis2026-05-07 20:05 EST

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May

REGNRegeneron Pharmaceuticals2026-06-04 11:00 EST

Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO

TEVATeva Pharmaceutical Industries2026-06-01 20:30 EST

Teva to Present at the Goldman Sachs Global Healthcare Conference

LYELLyell Immunopharma2026-06-01 12:00 EST

Lyell Immunopharma Announces Participation in Goldman Sachs 47th Annual Global Healthcare Conference 2026

GERNGeron2026-06-01 12:00 EST

Geron to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

ENTAEnanta Pharmaceuticals2026-05-28 11:00 EST

Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

COGTCogent Biosciences2026-05-27 12:00 EST

Cogent Biosciences Announces Participation in the 2026 Jefferies Global Healthcare Conference

View all latest news

Regeneron Pharmaceuticals

Regeneron is a biotechnology company built around antibody discovery, biologics development, and marketed therapies across eye disease, immunology, and oncology. The company’s platform and R&D engine make it one of the most scientifically respected names in public biotech.

Recent company news

REGNRegeneron Pharmaceuticals2026-06-04 11:00 EST

Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO

REGNRegeneron Pharmaceuticals2026-05-28 20:00 EST

Regeneron’s Ebola Antibody Recommended by World Health Organization for Investigational Use in Response to Current Bundibugyo Ebolavirus Outbreak

REGNRegeneron Pharmaceuticals2026-05-22 11:00 EST

Otarmeni™ (lunsotogene parvec) Receives EMA Filing Acceptance for Genetic Hearing Loss

REGNRegeneron Pharmaceuticals2026-05-21 21:01 EST

Lynozyfic® (linvoseltamab) Monotherapy Demonstrates Deep and Rapid Responses in All Treated Patients with Second-Line-Plus Systemic Amyloid Light Chain Amyloidosis

REGNRegeneron Pharmaceuticals2026-05-18 11:00 EST

Regeneron Announces Strategic Collaboration with Parabilis Medicines to Advance Novel Antibody-Helicon™ Conjugates Across Multiple Therapeutic Areas

Stock data

Close: 667.17 USD
Market cap: 63.21B USD
Exchange: NASDAQ
Sector: Antibody Drugs, Biopharma
Location: United States